Document text
Pneumococcal Vaccines Work Group
April 2025, ACIP meeting
April 15, 2025
Miwako Kobayashi
National Center for Immunization and Respiratory Diseases
1U.S. Centers for Disease Control and Prevention
Pneumococcal Vaccines Work Group
ACIP Members
•Jamie Loehr (Chair)
•Mini Kamboj
•George Kuchel
•Robert Schechter
Ex Officio Members
•Tina Mongeau (FDA)
•Nick Geagan (FDA)
•Uzo Chukwuma (IHS)
•Mamodikoe Makhene (NIH, primary)
•Meenu Upadhyay (NIH, alternate)
•Risa Claytor (HRSA)
Liaison Representatives
• Lynn Fisher (AAFP)
• Monica Ardura (AAP/COID)•Jason Goldman (ACP)
•Saba Hasan (ACP , alternate)
•James McAuley (IDSA)
•Eva Wong (NACI)
•Robert Hopkins (NFID, primary)
•William Schaffner (NFID, alternate)
•Michelle Floris -Moore (NMA)
•Mary Hayney ( APhA )
Consultants
•Monica Farley (Emory)
•Keith Klugman (Gates Foundation)
•Kathy Poehling (Wake Forest)
•Arthur Reingold (UC Berkley)
•Lorry Rubin (CCMC)
•Richard Zimmerman (U. of Pittsburgh)
CDC Contributors
Arctic Investigations Program
•Heather Scobie
CDC Lead
•Miwako KobayashiDivision of Bacterial Diseases
•Adam Cohen
•Ryan Gierke
•Noele Nelson
Immunization Safety Office
•Pedro Moro
Immunization Services Division
•Nancy Wong
Pneumococcal Work Group Terms of Reference
•Review evidence to inform use of new pneumococcal conjugate vaccines in
U.S. adults and children
ACIP Work Groups | ACIP | CDC 4
History of US Pneumococcal Vaccine Program,
1984 –2024
1984PPSV23: adults aged
≥65 years and
individuals with
underlying conditions
2000 2010 2019 2014 2012
PCV7: Children PCV13: Children
(replaced PCV7)PCV13: Adults with
immunocompromising
conditionsPCV13: All adults
aged ≥65PCV13 based on SCDM for all adults aged ≥65 years
PCV=pneumococcal conjugate vaccine, PPSV23=23 -valent pneumococcal polysaccharide vaccine, SCDM=shared clinical decision -making2021/2022
PCV15: Adults/childrenPCV20 : Adults2023
PCV20:
Children2024PCV21:
Adults
Current gaps in pneumococcal vaccine
recommendations
•Pregnant women
-Currently no recommendation
Adult Immunization Schedule by Medical Condition and Other Indication | Vaccines & Immunizations | CDC
Current gaps in pneumococcal vaccine
recommendations
•Hematopoietic Stem Cell Transplant (HSCT) recipients
-Different vaccination schedule compared with other risk conditions (last updated
in 2023)
-No clinical guidance for PCV21 use
Pneumococcal Vaccine for Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices, United S tates, 2023 | MMWR
Proposed work plan
•Review of literature on pneumococcal vaccine use in pregnant women
and HSCT recipients focusing on data on:
-Pneumococcal disease incidence and serotype distribution
-Vaccine efficacy, effectiveness, and impact
-Immunogenicity
-Safety
•Plan to present summary of findings and proposed language for updated
clinical guidance on pneumococcal vaccine use at the June 2025 ACIP
meeting
8
Thank you!
For more information, contact CDC
1-800- CDC- INFO (232 -4636)
TTY: 1 -888- 232- 6348 cdc.gov
The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the U. S. Centers for Disease Control and Prevention.
9